Header-Company-3

COMPANY

History

Apop Biosciences Pty Ltd was registered as a company in October 2016 (ACN 615 441 113) by founding director and medical researcher Dr Peter Wookey. We named our company Apop Biosciences after the major form of Programmed Cell Death (PCD) Apoptosis.

Dr Wookey discovered and developed the proprietary calcitonin receptor antibodies and protected the Intellectual Property in two patents. The IP is fully owned by Apop Biosciences.

Management Team

Chief Executive Officer

Dr Tina Lavranos

Dr Tina Lavranos

  • Over 16 yrs experience in Biotechnology industries
  • Experienced in R&D, business development, strategic alliances, operations and commercialisation
  • Expertise in the areas of oncology, stem cells and reproductive medicine

Chief Scientific Officer

Dr Peter Wookey

Dr Peter Wookey

  • Medical researcher University of Melbourne at the Austin Hospital
  • Co-inventor of CalRexinTM
  • Founder of Welcome Receptor Antibodies Pty Ltd

Independent Chair

Zoe Attwood - Independant Chair Apop Biosciences

Zoe Attwood

  • 20 yrs. experience as Company Director/Chair
  • Expertise in governance and innovation
  • Biotechnology and Food industries
  • Facilitator, governance training AICD and IoDNZ.

Currently Director NZDG Ltd, SealStone Ltd, NZ Government Primary Industries investment program advisor

Executive Director

Dr Peter Wookey

Dr Peter Wookey

  • Medical researcher University of Melbourne at the Austin Hospital
  • Co-inventor of CalRexinTM
  • Founder of Welcome Receptor Antibodies Pty Ltd

Non-executive Director

Dr Deborah Rathjen

Dr Deborah Rathjen

  • Experienced leader in biotechnology and pharmaceutical industries
  • Delivered in excess of $800 million in deals with Pharma including partnerships with Merck & Co., J&J, Abbott and Merck KGaA.
  • Seasoned entrepreneur, founded and successfully financed bio-pharmaceutical companies in oncology and neuroscience

Significant experience in M&A and company formation and financing, corporate strategy and licensing.